Key result
Higher mid-pregnancy MMP-12 linked to ~37% lower risk of subsequent preeclampsia.
Why the study?
Current preeclampsia prediction models need improvement, particularly for late-onset preeclampsia, and shared pathophysiology with cardiovascular disease suggests cardiovascular biomarkers may aid prediction.
Do mid-pregnancy cardiovascular biomarkers predict the subsequent development of preeclampsia in healthy women with singleton pregnancies?
Case-Control (n=629)
No
Do mid-pregnancy cardiovascular biomarkers predict the subsequent development of preeclampsia in healthy women with singleton pregnancies?
Odds Ratio: 0.63 (95% CI 0.48–0.82)
Mid-pregnancy cardiovascular biomarkers, particularly MMP-12, BNP, and IDUA, may improve the prediction of subsequent preeclampsia, including late-onset disease.
No takes yet. Share an insight, caveat, or question.
Mid-pregnancy cardiovascular biomarkers may aid preeclampsia risk stratification; leaves open prospective validation before clinical adoption.
Callbo et al. (2024) conducted a case-control in Preeclampsia (n=629). Mid-pregnancy cardiovascular biomarkers (MMP-12) vs. Controls (healthy pregnancies) was evaluated on Subsequent development of preeclampsia (aOR 0.63, 95% CI 0.48-0.82). Decreased mid-pregnancy levels of matrix metalloproteinase-12 (MMP-12) were significantly associated with an increased risk of subsequent preeclampsia (aOR 0.63).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: